Clinical Implication of the Deletion Status of ABL-BCR on Derivative Chromosome 9 in Chronic Myelogenous Leukemia.
- Author:
Young Kyung LEE
1
;
Young Ree KIM
;
Dong Soon LEE
;
Cha Ja SHE
;
Sung Soo YOON
;
Seon Yang PARK
;
Byoung Kook KIM
;
Han Ik CHO
Author Information
1. Department of Laboratory Medicine, Hallym University College of Medicine, Korea.
- Publication Type:Original Article
- Keywords:
Chronic myelogenous leukemia;
CML;
Philadelphia chromosome;
Fluorescence in situ hybridization;
FISH;
ABL deletion;
BCR deletion;
derivative chromosome 9
- MeSH:
Blast Crisis;
Chromosomes, Human, Pair 9*;
Disease Progression;
Disease-Free Survival;
Gene Deletion;
Gene Rearrangement;
Humans;
Hydrogen-Ion Concentration;
In Situ Hybridization, Fluorescence;
Interphase;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Philadelphia Chromosome;
RNA, Messenger;
Seoul
- From:The Korean Journal of Laboratory Medicine
2002;22(6):373-381
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The complementary ABL-BCR gene rearrangement is formed at chromosome 9 parallel to the Ph chromosome at der(22)t(9;22), which has been found deleted in a minority of chronic myelogenous leukemia (CML) patients. This study was designed to analyze the deletion status of ABL and/or BCR on derivative chromosome 9 and to evaluate the prognostic significance of the deletion of these genes in CML. METHODS: We studied 79 patients who were diagnosed as CML at Seoul National University Hospital between January 1997 and February 2002. The deletion status of ABL and BCR on derivative chromosome 9 was investigated by interphase fluorescent in situ hybridization (FISH) method. RESULTS: ABL deletion was detected in 14 (17.7%) patients and BCR deletion was observed in 8 patients (10.1%). Event-free survival time of the patients with ABL and/or BCR deletion (19.0%) was shorter than that of the patients without any deletion of these two genes (median, 40.0 months vs. 92.0 months)(P=0.027). Twenty seven patients progressed to blast crisis in this period. The period to blast crisis was also shorter in 8 patients with ABL and/or BCR deletion than in 19 patients without any gene deletion (P=0.044). The b2a2 mRNA type was more frequent in the patients with ABL deletion only than in the patients without any gene deletion (P=0.034). CONCLUSIONS: Event-free survival time and the period to blast crisis were significantly shorter in patients with deletion of ABL and/or BCR on derivative chromosome 9. ABL and/or BCR deletion can be a significant prognostic marker that indicates rapid disease progression.
